Chemomab Therapeutics Ltd. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount
Chemomab Therapeutics Ltd. (CMMB) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount of $148.00 thousand for the 12-month period ending 2024-12-31, per its 20-F filed 2026-03-23.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpense · last filed 2026-03-23
- Chemomab Therapeutics Ltd. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2020 was -$25.00K, a 102.09% decline from fiscal 2019.
- Chemomab Therapeutics Ltd. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2019 was $1.20M, a 624.24% increase from fiscal 2018.
- Chemomab Therapeutics Ltd. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2018 was $165.00K.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount 12 month |
|---|---|
| 2024-12-31 | $148.00K 20-F · filed 2026-03-23 |
| 2023-12-31 | $346.00K 20-F · filed 2026-03-23 |
| 2022-12-31 | $744.00K 20-F · filed 2025-04-04 |
| 2021-12-31 | $239.00K 20-F · filed 2024-03-28 |
| 2020-12-31 | -$25.00K 10-K · filed 2021-03-09 |
| 2019-12-31 | $1.20M 10-K · filed 2021-03-09 |
| 2018-12-31 | $165.00K 10-K · filed 2020-03-17 |